Dechra sees slowdown of growth in European sector

Dechra Pharmaceuticals said in a trading statement Tuesday that its first half has been in line with management expectations, but admitted its European Pharmaceuticals segment saw growth slow from 73.7 per cent to 61.4 per cent year-on-year.

Dechra Pharmaceuticals said in a trading statement Tuesday that its first half has been in line with management expectations, but admitted its European Pharmaceuticals segment saw growth slow from 73.7 per cent to 61.4 per cent year-on-year.

The reported divisional performance over the corresponding period last year, excluding Eurovet Animal Health, declined by 2.4% (an increase of 4.5% at constant currency), which the group said reflected an exceptional increase last year of £1.2m in the production of Vetoryl for the US market to ensure continuity of supply as it implemented manufacturing changes.

Planned changes to distribution arrangements in France and Germany also had an adverse effect on reported revenue, the firm said.

More positively, the integration of Eurovet continued to progress well and is delivering expected cost and revenue synergies.

In US Pharmaceuticals, revenue was ahead of the corresponding period last year by 10.0% (10.4% at constant currency), with strong growth seen in its DermaPet, Vetoryl and Felimazole products.

Revenues from the services division rose 5.1% compared to the prior year, while operating margin over the 12 months "demonstrated a modest improvement over the corresponding period last year".

The group commented that it made a "strong start to the financial year which is in line with the board's expectations".

The share price fell 2.8% to 625p on Tuesday morning.

NR

Recommended

Persimmon yields 12.3%, but can you trust the company to deliver?
Share tips

Persimmon yields 12.3%, but can you trust the company to deliver?

With a dividend yield of 12.3%, Persimmon looks like a highly attractive prospect for income investors. But that sort of yield can also indicate compa…
1 Jul 2022
Don’t try to time the bottom – start buying good companies now
Investment strategy

Don’t try to time the bottom – start buying good companies now

Markets are having a rough time, so you may be tempted to wait to try to call the bottom and pick up some bargains. But that would be a mistake, says …
1 Jul 2022
Share tips of the week – 1 July
Share tips

Share tips of the week – 1 July

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
1 Jul 2022
Bunzl: boring is good for business
Share tips

Bunzl: boring is good for business

Food-service distribution company Bunzl is not a terribly exciting business, but it looks cheap and could be a great investment, says Rupert Hargreave…
30 Jun 2022

Most Popular

UK house prices are definitely cooling off – but are they heading for a fall?
House prices

UK house prices are definitely cooling off – but are they heading for a fall?

UK house prices hit a fresh high in June, but as interest rates start to rise, the market is cooling John Stepek assesses just how much of an effect h…
30 Jun 2022
How to invest in copper, the most important metal in the world
Industrial metals

How to invest in copper, the most important metal in the world

As the world looks to electrify and try to move away from fossil fuels, copper looks set to be the biggest beneficiary. But how can you invest? Rupert…
30 Jun 2022
Don’t try to time the bottom – start buying good companies now
Investment strategy

Don’t try to time the bottom – start buying good companies now

Markets are having a rough time, so you may be tempted to wait to try to call the bottom and pick up some bargains. But that would be a mistake, says …
1 Jul 2022